Biossil Raises $70M to Rescue Failed Drug Candidates with AI

**Biossil has secured roughly $70 million in equity from OpenAI, Founders Fund and other investors to apply its AI platform to drug molecules that failed earlier trials.

Biossil emerged from stealth with a strategy to rescue drug candidates that were abandoned after early‑stage testing. Its AI system scans chemical libraries for molecules that showed promise but did not succeed in clinical development, then licenses or purchases those assets from the original owners.

The company announced about $70 million USD in equity financing, naming OpenAI, Founders Fund, Modern Capital, Staircase Ventures, Golden Ventures, Panache Ventures, Quiet Capital, 137 Ventures and DRI Healthcare as participants. Biossil reports it has around 30 employees split between a platform team handling technology, clinical, legal and quality work, and development teams advancing individual molecules. It says it has active trials for sickle cell disease, idiopathic pulmonary fibrosis, glioblastoma, breast cancer and Alzheimer’s disease, with nearly a dozen more indications in preparation.

By focusing on molecules that already passed safety screens, Biossil may shorten the typical drug‑development timeline, which often exceeds a decade and costs over $2 billion per approved therapy. However, the firm has not yet disclosed the phase, design (e.g., randomized controlled trial) or sample size of its ongoing studies, so any claim of efficacy remains preliminary. Investors will watch whether the AI‑driven approach can translate into positive trial readouts and eventual regulatory submissions.

Next, observers will track readouts from Biossil’s sickle cell and Alzheimer’s trials expected in late 2025, which could validate or refute the AI rescue model.